WO2012064300A3 - Desloratadine granules - Google Patents

Desloratadine granules Download PDF

Info

Publication number
WO2012064300A3
WO2012064300A3 PCT/TR2011/000242 TR2011000242W WO2012064300A3 WO 2012064300 A3 WO2012064300 A3 WO 2012064300A3 TR 2011000242 W TR2011000242 W TR 2011000242W WO 2012064300 A3 WO2012064300 A3 WO 2012064300A3
Authority
WO
WIPO (PCT)
Prior art keywords
desloratadine
granules
polymorph
enantiomer
solvate
Prior art date
Application number
PCT/TR2011/000242
Other languages
French (fr)
Other versions
WO2012064300A2 (en
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2012064300A2 publication Critical patent/WO2012064300A2/en
Publication of WO2012064300A3 publication Critical patent/WO2012064300A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Abstract

The present invention relates to granules comprising a therapeutically effective amount of desloratadine or a pharmaceutically acceptable salt, solvate, derivative, polymorph, hydrate or enantiomer thereof and production method thereof.
PCT/TR2011/000242 2010-11-11 2011-11-03 Desloratadine granules WO2012064300A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/09396 2010-11-11
TR2010/09396A TR201009396A2 (en) 2010-11-11 2010-11-11 Desloratadine granules

Publications (2)

Publication Number Publication Date
WO2012064300A2 WO2012064300A2 (en) 2012-05-18
WO2012064300A3 true WO2012064300A3 (en) 2012-08-02

Family

ID=45491748

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000242 WO2012064300A2 (en) 2010-11-11 2011-11-03 Desloratadine granules

Country Status (2)

Country Link
TR (1) TR201009396A2 (en)
WO (1) WO2012064300A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016140630A1 (en) * 2015-03-05 2016-09-09 PHARMACTIVE ILAÇ SANAYI VE TlCARET A. Ş. An effervescent composition comprising levocetirizine and pseudoephedrine
CN111398505B (en) * 2020-04-28 2022-04-08 健民药业集团股份有限公司 Method for simultaneously detecting contents of five components of traditional Chinese medicine for treating infantile enuresis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100274A (en) * 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
US20070048373A1 (en) * 2005-08-30 2007-03-01 Cima Labs Inc. Dried milled granulate and methods
US20070224266A1 (en) * 2006-03-24 2007-09-27 Pharmascience Inc. Descarbonylethoxyloratadine containing pharmaceutical composition
WO2010060635A2 (en) * 2008-11-28 2010-06-03 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising at least one stabilizing agent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985003707A1 (en) 1984-02-15 1985-08-29 Schering Corporation 8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO AD5,6 BDCYCLOHEPTA AD1,2-b BDPYRIDINE AND ITS SALTS, PROCESSES FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
TW522014B (en) 1997-02-07 2003-03-01 Sepracor Inc Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine
AU2277101A (en) 1999-12-20 2001-07-03 Schering Corporation Stable extended release oral dosage composition
US20070014855A1 (en) 2005-07-12 2007-01-18 Rahul Gawande S Stable desloratadine compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100274A (en) * 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
US20070048373A1 (en) * 2005-08-30 2007-03-01 Cima Labs Inc. Dried milled granulate and methods
US20070224266A1 (en) * 2006-03-24 2007-09-27 Pharmascience Inc. Descarbonylethoxyloratadine containing pharmaceutical composition
WO2010060635A2 (en) * 2008-11-28 2010-06-03 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising at least one stabilizing agent

Also Published As

Publication number Publication date
WO2012064300A2 (en) 2012-05-18
TR201009396A2 (en) 2012-05-21

Similar Documents

Publication Publication Date Title
NO2022043I1 (en) Asciminib or a pharmaceutically acceptable salt thereof, such as asciminib hydrochloride
IL238337A (en) Process for the manufacture of pharmaceutically active compounds
HK1203073A1 (en) Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
IL250439A0 (en) Use of fingolimod, or a phosphate derivative thereof or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of multiple sclerosis
AP3589A (en) A novel 1,2,3,4-tetrahydroquinoline derivative useful for the treatment of diabetes
EP2582671A4 (en) Process for the preparation of a single enantiomer of 3-aminopiperidine dihydrochloride
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
EP2412706A4 (en) Novel hydroxamate derivative, a production method for the same, and a pharmaceutical composition comprising the same
HRP20170600T1 (en) Process for the production of biscuits having improved organoleptic properties
EP2594554A4 (en) Biaryl amide derivative or pharmaceutically acceptable salt thereof
PL2530139T3 (en) Process for production of flavor granules
WO2012118308A3 (en) Composition for preventing and treating cardiovascular diseases, containing pyrazole derivative
WO2011023954A3 (en) Polymorphic forms of manidipine
WO2012030170A3 (en) Novel compound acting as a cannabinoid receptor-1 inhibitor
WO2012018791A3 (en) Preparation of prasugrel hydrochloride
WO2010137040A3 (en) Novel pharmaceutical compositions of ranolazine
WO2011021864A3 (en) Novel compound for complementing anticancer drugs, a production method for the same, a composition for complementing anticancer drugs comprising the same, and a method for reducing resistance to anticancer drugs using the same
WO2012064300A3 (en) Desloratadine granules
EP2460802A4 (en) Trifluoromethylthiophenium derivative salts, process for produciton thereof, and process for production of trifluoromethyl-containing compounds using same
ZA201303872B (en) Improved process for the preparation of 2-trifluoromethyl-5-(1-substituted)alkylpyridines
WO2013114397A3 (en) Pharmaceutically acceptable salt of brinzolamide and composition thereof
WO2011036677A3 (en) Sustained release composition of ranolazine
SI2164468T1 (en) Method for the production of a form of administration of a medicament
ZA201000159B (en) Process for the production of substituted 5-quinolyl-oxazoles and pharmaceutically acceptable salts thereof
PL391495A1 (en) Method for production of 3�, 11?-dihydroxy-17a-oxa-D-homo-5?-androstan-17-one

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11808730

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11808730

Country of ref document: EP

Kind code of ref document: A2